TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Imcheck Therapeutics
ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025

ImCheck Therapeutics presented promising clinical data for ICT01, a γ9δ2 T-cell activator, showing rapid and durable responses in newly diagnosed AML patients when combined with azacitidine and venetoclax, with an encouraging early overall survival signal.

Insights
ZS   positive

Recognized for supporting secure access solutions in healthcare and regulated industries


IPSEY   positive

Pursuing acquisition of ImCheck Therapeutics, suggesting strategic interest in the company's innovative immunotherapy technology